Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China

Table 4 Univariate and Multivariate Cox Regression Analyses Exploring Associations between A Sustained SR or Sustained CR and Baseline/On-Treatment/Off-Treatment Characteristics

	Sustained Serological Response				Sustained Complete Clinical Response
	Univariate		Multivariate		Univariate		Multivariate
	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p
Baseline
Age	1.01 (0.99, 1.02)	0.44			1.01 (0.94, 1.07)	0.82
Gender (Male)	1.24 (0.60, 2.55)	0.57			1.40 (0.84, 2.34)	0.20
BMI	1.10 (0.97, 1.25)	0.13			0.97 (0.82, 1.15)	0.73
HBV Genotype (B)	0.63 (0.36, 1.13)	0.12	0.42 (0.22, 0.81)	0.01	0.50 (0.18, 1.36)	0.17
ALT< 3*ULN	1.15 (0.58, 2.26)	0.70			0.99 (0.35, 2.78)	0.99
HBsAg (Log10 IU/mL)	0.97 (0.63, 1.52)	0.91			1.00 (0.45, 2.21)	0.99
HBeAg (Log10 IU/mL)	1.29 (0.84, 1.98)	0.24			1.36 (0.68, 2.74)	0.39
HBV DNA (Log10 IU/mL)	0.96 (0.69, 1.31)	0.78			0.83 (0.44, 1.56)	0.56
PEG-IFN alfa-2b (48-week scheme)	3.69 (1.96, 6.92)	< 0.01	5.00 (2.50, 10.00)	< 0.01	7.69 (2.00, 25.00)	< 0.01	7.07 (1.87, 26.79)	< 0.01

All baseline and selected on treatment characteristics were analyzed (N = 322) by univariate analysis and variables with a p-value< 0.25 entered into multivariate model where variables were eliminated by hierarchical forward with switching method until p values for all retained variables were less than 0.1; Wald test method was used to give p values for variable’s regression coefficient
Sustained serological response was defined as Hbe seroconversion at the end of P05170 and in the LTFU
^†All patients who have a sustained response were free of any additional antivirals. No actual HR and 95%CI will be calculated
^‡Not applicable: the duration of follow-up by year is deemed as having a probability distribution in survival function and was not incorporated into the Cox model as an independent variable

ISSN: 1471-230X